openPR Logo
Press release

Anti-Viral Drugs Market Growth, Trends and Value Chain 2016-2026 by FMI

10-06-2016 02:24 PM CET | Health & Medicine

Press release from: Future Market Insights

Anti-Viral Drugs Market Growth, Trends and Value Chain

Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses. The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy. Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive. The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body. The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.

Anti-viral Drugs Market: Drivers and Restraints

As of October 2013, according to WHO, there were around 35.3 Mn people globally, infected with HIV. Therefore, increased viral infection incidences is one of the important factors that drives the anti-viral drugs market growth. Because of the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy and others, are being introduced in the market. Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth. On the other hand, high risk of failure, high cost of R&D and therapy, and government austerity are some of threats expected to hinder the growth of market. These are some factors anticipated to fuel growth of global anti-viral drugs market within the forecast period of 2016-2026. However, increasing usage of natural products and high cost of developing drugs are the key challenges faced by the market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1951

Anti-viral Drugs Market: Segmentation

The global anti-viral drugs market is classified on the basis of product type, end user and geography.

Based on product type, the global anti-viral drugs market is segmented into the following:

Hepatitis-C antivirals

HIV antivirals

Herpes antivirals

Hepatitis-B antivirals

Influenza antivirals

Others (Pneumonia, Flu, etc.)

Based on end user, the global anti-viral drugs market is segmented into the following:

Hospitals

Clinics

Ambulatory Surgical Centers

Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1951

Anti-viral Drugs Market: Overview

The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010. At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year. Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.

Anti-viral Drugs Market: Regional Overview

Region wise, the global anti-viral drugs market is classified into regions namely, North America, Eastern Europe, Western Europe, Latin America, Japan, Asia-Pacific, Middle East and Africa. According to WHO, in countries with Major ART scale-up such as Brazil or China, the death rate among people living with HIV has decreased by 80%. In 2015, in India the number of people living with HIV were 2.1 Mn and in U.S. the number was around 1.2 Mn in the year 2013.

Full Report Analysis@ http://www.futuremarketinsights.com/reports/anti-viral-drugs-market

Anti-viral Drugs Market: Key Players

Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.

About Us:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

Contact Us:
Future Market Insights
616 Corporate Way,
Suite 2-9018,
Valley Cottage,
New York 10989,
United States
Tel: +1-347-918-3531
Fax: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website: www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-Viral Drugs Market Growth, Trends and Value Chain 2016-2026 by FMI here

News-ID: 370206 • Views:

More Releases from Future Market Insights

AI in IoT Market Set to Reach USD 172.8 Billion by 2035 with 6.4% CAGR Amid Rising Digital Transformation
AI in IoT Market Set to Reach USD 172.8 Billion by 2035 with 6.4% CAGR Amid Risi …
The AI in IoT market is witnessing rapid expansion as enterprises across industries increasingly integrate artificial intelligence with Internet of Things (IoT) systems. Valued at USD 92.9 billion in 2025, the market is projected to reach USD 172.8 billion by 2035, representing a compound annual growth rate of 6.4%. The integration of AI into IoT infrastructure enables predictive analytics, real-time monitoring, and automated control across multiple applications, transforming how businesses
Catalog Management System Market Poised to Reach USD 4.2 Billion by 2035 with Advanced Technology Integration
Catalog Management System Market Poised to Reach USD 4.2 Billion by 2035 with Ad …
The catalog management system (CMS) market is experiencing steady and strategic growth, with its value projected to rise from USD 1.9 billion in 2025 to USD 4.2 billion by 2035, reflecting a compound annual growth rate (CAGR) of 8.1%. The market expansion is primarily fueled by businesses' growing need for centralized product information, streamlined digital operations, and enhanced customer experiences across increasingly complex sales channels. As e-commerce continues to penetrate global
HIFI Electronics Market Set to Double by 2035, Driven by Premium Audio and Technological Innovation
HIFI Electronics Market Set to Double by 2035, Driven by Premium Audio and Techn …
The global HIFI electronics market is poised for remarkable growth over the next decade, projected to expand from USD 17,243.4 million in 2025 to USD 37,227.2 million by 2035. This impressive growth trajectory, representing an absolute increase of nearly USD 19,983.8 million and a compound annual growth rate (CAGR) of 8%, reflects the rising global appetite for premium audio experiences and high-fidelity sound reproduction across personal and professional applications. The expansion
Interrogation Table Market to Reach USD 435.7 Million by 2035, Driven by Security Infrastructure Expansion
Interrogation Table Market to Reach USD 435.7 Million by 2035, Driven by Securit …
The global interrogation table market, valued at USD 321.1 million in 2025, is set to grow steadily to USD 435.7 million by 2035, registering a moderate CAGR of 3.1%. This trajectory reflects a market gradually approaching maturity, where incremental demand for specialized security furniture outweighs rapid expansion. The early stage from 2025 to 2028 is expected to see modest increases in annual revenues, primarily linked to new infrastructure development across

All 5 Releases


More Releases for HIV

HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792 This latest report researches the industry structure, sales, revenue,
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways